Liquidia Corp

LQDA remains in a Stage 2 advance with persistent higher highs and higher lows under rising EMAs. The recent shallow pullback into the 9 EMA/21 EMA zone held firm, offering a favorable buy opportunity. Momentum remains intact and relative strength supports further upside. We recommend buying now on minor pullbacks into the rising short-term EMAs for continuation participation.

• ↑Q1 2026 net product sales reached $129.9 M, up 44% QoQ
• ↑Utrepia market share expanded from 10% to 23% shortly after launch
• ↓Negative earnings yield and weak book-to-price indicate valuation concerns